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PRIMARY SCLEROSING CHOLANGITIS:
PALLIATIVE SURGERY OR TRANSPLANTATION?
ABSTRACT
Ismail, T., Angrisani, L., Powell, J.E., Hubscher, S., Buckels, J., Neuberger, J.,
Elias, E., McMaster, P. (1991) Primary sclerosing cholangitis: surgical options,
prognostic variables and outcome. British Journal of Surgery; 78 564-567
The natural history of primary sclerosing cholangitis (PSC) is poorly defined and its
management remains controversial. Forty-eight symptomatic patients (median age
39 years, range 8-67 years; 30 male) with PSC were reviewed retrospectively. Thirty
patients had infllammatory bowel disease. Four patients (8 per cent) developed or
had an associated malignancy. Twenty-one (44 per cent) died; overall 5 year
actuarial survival was 30 per cent. Twenty-three patients had 27 non-transplant
related biliary operations (16 patients specifically for PSC of whom 12 died. Serum
bilirubin was the only parameter to improve after biliary surgery. Seventeen
patients (35 per cent) underwent orthotopic liver transplantation (OLT) of whom
nine are currently alive (1 year projected survival of 55 per cent). Previous biliary
surgery correlated with a poor outcome (P<0.0001) after OLT. Being male,
presence of cirrhosis, duration of symptomatic disease (> 3 years) and a serum
bilirubin level > 100 pmol/l at presentation, were independently associated with a
poor outcome (P< 0.05). These data provide evidence that PSC is a progressive
disease and conventional surgical options have little influence on the outcome.
Previous biliary surgery adversely affects outcome following OLT. For progressive
liver disease, liver transplantation should be considered the treatment of choice.
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Primary sclerosing cholangitis is an idiopathic disease, with an extremely broad
clinical spectrum. Because of this broad spectrum, most published series, which
contain only a modest number of patients because of the rarity of the disorder, give
a somewhat skewed outlook of the natural history. For instance, there are some
series that suggest the disease runs an exceedingly benign course, with the vast
majority of patients surviving five years without therapy. Other series, including
the group of 48 patients presented by Ismail et al., demonstrate a five year survival
of only 30%. The reason for these disparities is that each series consists of selected
patients. The means of selection determine the subsequent clinical course. Only
when one institution accumulates a large enough clinical experience, or many
smaller series from a variety of institutions are combined, will we accurately
understand the natural history of this disorder.
The current series consists of 48 symptomatic patients, a substantial number of
whom had far advanced liver disease. Presenting features included variceal hemorr-
hage in 21%, and encephalopathy in 25%. Histology was available from 45 of their
patients, and in 23, or 51%, established cirrhosis was present. Thus this series
consists of patients with well advanced sclerosing cholangitis, many ofwhom would
not be candidates for any other therapeutic intervention except liver transplan-
tation.
Therefore, their conclusion that conventional surgical options have little
influence on the outcome is inevitable, since to benefit from conventional surgical
therapy only mild to moderate liver disease can be present. From our institution,
as well as from others, there is ample evidence to suggest that either direct surgical
intervention with hepatic duct resection and long-term stenting with silastic tran-
shepatic biliary stents, or percutaneous dilatation of strictures, can indeed influence
the subsequent course that these patients manifest, if far advanced liver disease is
not present. Each series published to date that advocates reconstructive procedures
has clearly demonstrated that if cirrhosis is present, nothing less than liver
transplantation is likely to help. These patients have end stage disease, and
obviously will not benefit from a biliary reconstruction. If one is to influence the
subsequent course of sclerosing cholangitis, the intervention obviously has to be
performed prior to the development of end stage liver disease. This point is not
emphasized adequately in the current manuscript. Another statement the authors
make that many might disagree with is that previous surgery on the biliary tract
predicts a poor outcome if followed by orthotopic liver transplantation. Even
though that appeared to be the case in the current series, in the larger series
reported by the Pittsburgh transplant group, patients with sclerosing cholangitis
who had been operated upon previously did just as well as those who had not been
operated upon. Without question the hepatectomy and transplant are technically
more difficult if prior surgery has been undertaken, but ultimate outcome should
not be affected. Clearly if a direct biliary tract procedure will prevent the need for
liver transplantation, or even if it will delay it for a several year period, it should be
performed. That of course is the crux of the argument. Whether or not a procedure
performed directly on the biliary tract prior to the development of cirrhosis, willHPB INTERNATIONAL 277
alter the natural history of the disease, and delay or prevent the development or
cirrhosis. Data from our unit as well as others suggests that to be the case. The
current series, many of whom have end stage disease, cannot answer that question.
This series is a large group of ill patients with end stage disease, and the authors are
to be complimented on their results with this extremely difficult high risk group.
John L. Cameron
The Johns Hopkins University
School of Medicine
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COMMON BILE DUCT STONES ERCP OR
SURGERY?
ABSTRACT
Stain, S. C., Cohen, H., Tsuishoysha, M., Donovan, A.J. (1991)
Choledocholithiasis Endoscopic sphincterotomy or common bile duct exploration.
Annals of Surgery; 213:627-634
A prospective randomized trial was conducted of preoperative endoscopic sphincter-
otomy and surgery (ES&S) or surgery alone (SA) in 52 patients with cholecystolithia-
sis and choledocholithiasis that were candidates for elective surgery. After ES&S